Safety and immune responses in children after concurrent or sequential 2009 H1N1 and 2009-2010 seasonal trivalent influenza vaccinations

Journal of Infectious Diseases

Volumn 206, Issue 6, 2012, Pages 828-837

  Frey, Sharon E ^a   Bernstein, David I ^b   Gerber, Michael A ^b   Keyserling, Harry L ^c   Munoz, Flor M ^d   Winokur, Patricia L ^e   Turley, Christine B ^f   Rupp, Richard E ^f   Hill, Heather ^g   Wolff, Mark ^g   Noah, Diana L ^h   Ross, Allison C ^c   Cress, Gretchen ^e   Belshe, Robert B ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF IOWA   (United States)

^f UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^g EMMES CORPORATION   (United States)

^h SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY; INFLUENZA VACCINE; VIRUS ANTIGEN;

2009 H1N1 INFLUENZA; ADOLESCENT; ARTICLE; BLOOD SAMPLING; CHILD; CONTROLLED STUDY; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INJECTION SITE REACTION; IRRITABILITY; MALE; MYALGIA; NAUSEA; NORMAL HUMAN; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; SINGLE DRUG DOSE; VOMITING;

ADOLESCENT; AGING; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; SEASONS;

EID: 84865726229     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis445     Document Type: Article

References (24)

1. Garten RJ, Davis CT, Russel CA, et al. Antigenic and genetic characteristics of swine-origin 2009 A (H1N1) influenza viruses circulating in humans. Science 2009; 325:197-201.
2. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009; 360:2605-15. [Erratum, N Engl J Med 2009; 361:102].
3. Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009; 361:1935-44.
4. France AM, Jackson M, Schrag S, et al. Household transmission of influenza A (H1N1) virus after a school-based outbreak in New York City, April-May 2009. J Infect Dis 2010; 201:984-92.
5. Centers for Disease control and Prevention. Update: novel influenza A (H1N1) virus infections-worldwide, may 6, 2009. MMWR Morb Mortal Wkly 2009; 58:453-8.
6. Centers for Diseases Control and Prevention. Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep 2009; 58:521-4.
7. Hancock K, Veguilla V, Lu X, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009; 361:1945-52.
8. Wu J, Xu F, Lu L, et al. Safety and effectiveness of a 2009 H1N1 vaccine in Beijing. N Engl J Med 2010; 363:2416-23.
9. Zhu F-C, Wang H, Fang H-H, et al. A nnovel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009; 361:2414-23.
10. Arguedas A, Soley C, Lindert K. Responses to 2009 H1N1 vaccine in children 3 to 17 years of age. N Engl J Med 2010; 362:370-2.
11. Talaat KR, Greenberg ME, Lai MH, et al. A single dose of unadjuvanted novel 2009 H1N1 vaccine is immunogenic and well tolerated in young and elderly adults. J Infect Dis 2010; 202:1327-37.
12. Greenberg ME, Lai MH, Hartel GF, et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009; 361:2405-13.
13. Madhun AS, Akselsen PE, Sjursen H, et al. An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. Vaccine 2011; 29:266-73.
14. Clark TW, Pareek M, Hoschler K, et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009; 361:2424-35.
15. Mallory RM, Malkin E, Ambrose CS, et al. Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials. PLoS One 2010; 5:e13755.
16. Prevention and control of seasonal influenza with vaccines: recommendation of the advisory committee of immunizations practices, 2009.
17. Noah DL, Hill H, Hines D, et al. Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure. Clin Vacc Immunol 2009; 16:558-66.
18. Lu Y, Jacobson DL, Ashworth LA, et al. Immune response to influenza vaccine in children with inflammatory bowel disease. Am J Gastroenterol 2009; 104:444-53.
19. Treanor JJ, Schiff GM, Hayden FG. Safety and immunogenicity of abaculovirus-expressed hemagglutinin influenza vaccine a randomized controlled trial. J Amer Med Assn 2007; 297:1577-82.
20. Nolan T, McVernon J, Skeljo M, et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in infants and children. JAMA 2010; 303:37-46.
21. Liang XF, Wang HQ, Wang JZ, et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomized, placebo-controlled trial. Lancet 2010; 375: 56-66.
22. Fiore AE, Neuzil KM. 2009 influenza A (H1N1) monovalent vaccines for children. JAMA 2010; 303:73-4.
23. National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention. Use of influenza A (H1N1) 2009 monovalent vaccine. MMWR Recomm Rep 2009; 58(RR-10):1-8.
24. World Health Organization. Pandemic influenza A (H1N1) 2009 virus vaccine conclusions and recommendations from the october 2009 meeting of the immunization strategic advisory group of experts. Wkly Epidemiol Rec 2009; 84:505-8.